These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 3207617)

  • 21. [Digital blood flow measurement by venous occlusion plethysmography in Raynaud's phenomenon. Value of the rewarming test].
    Cristol R; Debray J
    J Mal Vasc; 1986; 11(1):85-9. PubMed ID: 3944527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of cold and emotional stress in Raynaud's disease and scleroderma.
    Freedman RR; Ianni P
    Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
    Yocum DE; Hodes R; Sundstrom WR; Cleeland CS
    J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raynaud's phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis.
    Sandqvist G; Wollmer P; Scheja A; Wildt M; Hesselstrand R
    Scand J Rheumatol; 2018 May; 47(3):206-209. PubMed ID: 28803485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term effect of cold provocation on single-breath carbon monoxide diffusing capacity in subjects with and without Raynaud's phenomenon.
    Gastaud M; Dolisi C; Bermon S; Gaudin P; Defauw G; Ardisson JL
    Clin Exp Rheumatol; 1995; 13(5):617-21. PubMed ID: 8575140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Laser Doppler spectral analysis of patients with Raynaud's phenomenon during a standardized thermal test].
    Léger P
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S28-9. PubMed ID: 9922888
    [No Abstract]   [Full Text] [Related]  

  • 28. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hand involvement in systemic sclerosis].
    Mouthon L
    Presse Med; 2013 Dec; 42(12):1616-26. PubMed ID: 24268960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis.
    Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papazoglou S; Papamichael C; Moulopoulou D; Kostamis P; Stamatelopoulos S; Moulopoulos S
    Clin Exp Rheumatol; 1998; 16(2):135-40. PubMed ID: 9536388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy.
    Wasserman A; Brahn E
    Semin Arthritis Rheum; 2010 Oct; 40(2):137-46. PubMed ID: 19878974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
    Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
    Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud's phenomenon: color Doppler flow imaging study.
    Aikimbaev KS; Oğuz M; Ozbek S; Demirtaş M; Birand A; Batyraliev T
    Angiology; 1996 May; 47(5):475-80. PubMed ID: 8644944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of vasospastic attacks despite digital nerve block in Raynaud's disease and phenomenon.
    Freedman RR; Mayes MD; Sabharwal SC
    Circulation; 1989 Oct; 80(4):859-62. PubMed ID: 2791249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood flow through the brachial artery at different temperatures in patients with Raynaud's phenomenon.
    Savin E; Kedra W; Oliva I; Prerovský I; Martineaud JP
    Cor Vasa; 1989; 31(4):299-305. PubMed ID: 2805704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Cutolo M
    Arthritis Rheum; 2010 Sep; 62(9):2595-604. PubMed ID: 20506306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.